Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Drug-Resistant Epilepsy Clinical Trial

Official title:
An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

Status Terminated

Clinical Trial Summary

The purpose of the study is to evaluate the long-term safety and tolerability of Padsevonil administered at individualized doses as adjunctive treatment for subjects with drug-resistant epilepsy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03370120
Study type	Interventional
Source	UCB Pharma
Contact
Status	Terminated
Phase	Phase 2
Start date	August 27, 2018
Completion date	December 11, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03893916` - MEG Versus EEG HR for the Localization of the Epileptogenic Zone as Part of the Pre-surgical Assessment of Epilepsy	N/A
Terminated	`NCT03739840` - A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy	Phase 3
Completed	`NCT03373383` - Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy	Phase 2
Recruiting	`NCT05769634` - Electrophysiological Read-Out of Interoceptive Processing	Early Phase 1